Get the Stockscreener App
13.62
5.66%
0.73
After Hours:
13.49
-0.13
-0.95%
Liquidia Corp stock is traded at $13.62, with a volume of 1.48M.
It is up +5.66% in the last 24 hours and up +22.70% over the past month.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$12.89
Open:
$13
24h Volume:
1.48M
Relative Volume:
1.89
Market Cap:
$1.15B
Revenue:
$17.49M
Net Income/Loss:
$-78.50M
P/E Ratio:
-11.35
EPS:
-1.2
Net Cash Flow:
$-52.85M
1W Performance:
+19.89%
1M Performance:
+22.70%
6M Performance:
+22.92%
1Y Performance:
+5.66%
1-Day Range:
$12.93
$13.78
1-Week Range:
$11.45
$13.78
52-Week Range:
$8.26
$16.99
Liquidia Corp Stock (LQDA) Company Profile
Name
Liquidia Corp
Sector
Industry
Phone
919.328.4400
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Compare LQDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
13.62 | 1.15B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-16-24 | Initiated | Raymond James | Outperform |
| Jun-25-24 | Initiated | Oppenheimer | Perform |
| Jan-05-24 | Reiterated | Needham | Buy |
| Sep-19-22 | Resumed | Wedbush | Underperform |
| Sep-01-22 | Downgrade | Wedbush | Neutral → Underperform |
| Jul-22-22 | Initiated | Ladenburg Thalmann | Buy |
| May-31-22 | Initiated | BTIG Research | Buy |
| May-26-22 | Initiated | BofA Securities | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Nov-20-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-05-18 | Initiated | Wedbush | Outperform |
| Aug-20-18 | Initiated | Jefferies | Buy |
| Aug-20-18 | Initiated | Needham | Buy |
View All
Liquidia Corp Stock (LQDA) Latest News
Barclays PLC Purchases 72,591 Shares of Liquidia Co. (NASDAQ:LQDA) - Defense World
Liquidia Corp CFO Michael Kaseta sells shares worth $275,298 By Investing.com - Investing.com Australia
Rajeev Saggar Sells 6,249 Shares of Liquidia Co. (NASDAQ:LQDA) Stock - MarketBeat
Roger Jeffs Sells 22,343 Shares of Liquidia Co. (NASDAQ:LQDA) Stock - MarketBeat
Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler Sells 16,393 Shares - MarketBeat
Liquidia's chief medical officer Rajeev Saggar sells $73,613 in stock By Investing.com - Investing.com Australia
Liquidia's chief commercial officer sells shares worth $98,504 By Investing.com - Investing.com Australia
Liquidia’s chief commercial officer sells shares worth $98,504 By Investing.com - Investing.com Nigeria
Liquidia Corp chief business officer sells $56,650 in stock By Investing.com - Investing.com South Africa
Liquidia's chief commercial officer sells shares worth $98,504 - Investing.com India
Liquidia's chief medical officer Rajeev Saggar sells $73,613 in stock - Investing.com India
Liquidia Corp general counsel sells shares worth $193,109 - Investing.com India
Liquidia Corp CFO Michael Kaseta sells shares worth $275,298 - Investing.com
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
Liquidia’s (LQDA) Buy Rating Reiterated at Needham & Company LLC - Defense World
Analysts Set Liquidia Co. (NASDAQ:LQDA) Price Target at $25.38 - MarketBeat
Liquidia's (LQDA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Breaking Down Liquidia: 4 Analysts Share Their Views - Benzinga
Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Yutrepia's Launch: A Catalyst for Liquidia (LQDA) - substack.com
Liquidia Co. (NASDAQ:LQDA) Shares Sold by Geode Capital Management LLC - MarketBeat
Geode Capital Management LLC Cuts Position in Liquidia Co. (NASDAQ:LQDA) - Defense World
Barclays PLC Buys 72,591 Shares of Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Barclays PLC Boosts Stock Position in Liquidia Co. (NASDAQ:LQDA) - Defense World
Jim Cramer’s Hidden Gem: Why Liquidia Corporation (LQDA) Is the Undervalued Stock You Need to Know - Insider Monkey
State Street Corp Decreases Stock Holdings in Liquidia Co. (NASDAQ:LQDA) - Defense World
State Street Corp Has $21.75 Million Holdings in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Liquidia (NASDAQ:LQDA) Research Coverage Started at Wells Fargo & Company - Defense World
Wells Fargo & Company Initiates Coverage on Liquidia (NASDAQ:LQDA) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $833,000 Stake in Liquidia Co. (NASDAQ:LQDA) - Defense World
Liquidia Co. (NASDAQ:LQDA) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Analysts Set Liquidia Co. (NASDAQ:LQDA) Price Target at $24.00 - MarketBeat
Charles Schwab Investment Management Inc. Purchases 230,820 Shares of Liquidia Co. (NASDAQ:LQDA) - Defense World
Liquidia stock gains after win in patent dispute with United Therapeutics - Seeking Alpha
Here’s Arquitos Capital Management’s Updates on Liquidia (LQDA) - Yahoo Finance
Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect? - Yahoo Finance
Zurcher Kantonalbank Zurich Cantonalbank Has $187,000 Stake in Liquidia Co. (NASDAQ:LQDA) - Defense World
BNP Paribas Financial Markets Raises Stock Position in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Anson Funds Management LP Invests $1.76 Million in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Liquidia (NASDAQ:LQDA) Shares Down 4.2%Should You Sell? - MarketBeat
Whitefort Capital Management LP Has $17.02 Million Stake in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Judge Signals Doubt on Liquidia's FDA Drug Exclusivity Fight - Bloomberg Law
Cinctive Capital Management LP Takes $444,000 Position in Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Liquidia CFO and COO Michael Kaseta sells shares worth $12,557 By Investing.com - Investing.com Nigeria
Liquidia Corp general counsel Russell Schundler sells $12,235 in stock - Investing.com India
Liquidia's chief business officer sells $5,237 in stock By Investing.com - Investing.com Canada
Liquidia's chief commercial officer sells $6,284 in stock By Investing.com - Investing.com Canada
Liquidia's chief commercial officer sells $6,284 in stock - Investing.com India
Liquidia CFO and COO Michael Kaseta sells shares worth $12,557 - Investing.com
Liquidia's chief business officer sells $5,237 in stock - Investing.com
HighVista Strategies LLC Buys 59,193 Shares of Liquidia Co. (NASDAQ:LQDA) - MarketBeat
Liquidia Corp Stock (LQDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):